Plain-English translation of NCT06726564 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage trial testing MT027, a new medication given as an injection directly into the space around your lungs. The study is designed to find the safest dose and understand how your body responds to this treatment. It's being offered to people with advanced cancers that have spread to the lung lining and have not responded to standard treatments.
Many patients with tumors affecting the lung lining do not benefit from standard chemotherapy or other treatments, and fluid builds up in the space around the lungs causing breathing problems. This study is exploring whether giving medication directly to that area—rather than through the entire body—might work better and cause fewer side effects.
You likely qualify if…
You likely don't qualify if…
In your first cycle, you will receive a single injection of the medication directly into the space around your lungs through a needle puncture. You will then stay in the hospital for at least 7 days so doctors can monitor you closely for any side effects, with access to emergency care. After safety checks on days 14 and 28, if you are doing well and your cancer is not getting worse, you may receive additional injections every 3 weeks. You will continue treatment as long as it is helping you and you are tolerating it well, though treatment can be reduced or paused if you experience unwanted effects.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China